BioPharma Dive 2026-02-19 Altesa, run by former Trump official, raises $75M for well-traveled lung drug
BioPharma Dive 2026-02-19 FDA leaders say one pivotal trial, not two, should be ‘default’ for drug approvals
BioPharma Dive 2026-02-18 FDA accepts BMS protein degrader for review; Disc rare disease drug rejected
BioPharma Dive 2026-02-17 How to evaluate prospective diagnostic laboratory partners for your patient support program
BioPharma Dive 2026-02-13 Lyell starts first-of-its-kind CAR-T trial; New coalition aims to boost European biotechs
BioPharma Dive 2026-02-12 Earnings roundup: Neurocrine slumps, Alnylam battles skeptics and Ascendis eyes a competitor
BioPharma Dive 2026-02-12 Lowering drug costs is on Republicans’ minds. Democrats say GOP policies don’t help.
BioPharma Dive 2026-02-12 Sanofi, looking for more ‘rigor,’ swaps CEO Hudson for ex-Merck KGaA chief Garijo